New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 12, 2014
08:55 EDTCNAT, CNAT, CNAT, CNAT, CNAT, CNATConatus Pharmaceuticals management to meet with Roth Capital
Meetings to be held in Europe March 12-14 hosted by Roth Capital.
News For CNAT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2015
07:19 EDTCNATConatus results at EASL meeting support emricasan registration pathway in NASH
Conatus Pharmaceuticals announced that posters providing detailed results from four recently completed clinical trials of emricasan, the company's first-in-class, orally active pan-caspase protease inhibitor, are being presented this week at The International Liver Congress 2015. Results from the company's Phase 2 double-blind, placebo-controlled clinical trial of emricasan in patients with acute-on-chronic liver failure, or ACLF, and Phase 2 double-blind, placebo-controlled clinical trial of emricasan in patients with nonalcoholic fatty liver disease, or NAFLD, including the subset of NAFLD patients with nonalcoholic steatohepatitis, or NASH, are addressed in two late-breaker posters. Conatus intends to include NASH-driven cirrhosis in its initial registration strategy for emricasan.
April 15, 2015
17:21 EDTCNATHealthCor reports 5.22% passive stake in Conatus

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use